A phase II randomized trial of doxorubicin (DXR) and gemcitabine (GMZ) administered in patients with metastatic breast cancer (MBC)

被引：0
|
作者：
A Bensalem
K Bouzid
机构：
[1] Chu Dr Benbardis,Medical Oncology
来源：
Breast Cancer Research | / 7卷
关键词：
Breast Cancer; Doxorubicin; Neutropenia; Gemcitabine; Partial Response;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Final results of first-line weekly paclitaxel plus gemcitabine in metastatic breast cancer (MBC): an AERO phase II trial
    Mousseau, M.
    Serin, D.
    Goubely-Brewer, Y.
    Petit, T.
    Priou, F.
    Zelek, L.
    BULLETIN DU CANCER, 2007, 94 (06) : 569 - 570
  • [42] A phase II study of a combination of pemetrexed (Pem) and gemcitabine (Gem) in patients with metastatic breast cancer (MBC): An NCCTG study.
    Ma, CX
    Steen, P
    Rowland, KM
    Niedringhaus, RD
    Kugler, JW
    Ingle, JN
    Perez, EA
    Adjei, AA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 36S - 36S
  • [43] Phase II study of weekly gemcitabine in patients with metastatic breast cancer (mbc) relapsing or failing on both an anthracycline (A) and a taxane (T).
    Smorenburg, C
    Bontenbal, M
    Seynaeve, C
    van Zuylen, L
    de Heus, G
    Verweij, J
    de Wit, R
    ANNALS OF ONCOLOGY, 2000, 11 : 31 - 31
  • [44] Clinical and safety data of a phase I/II trial with imatinib and vinorelbine for patients with metastatic breast cancer (MBC).
    Mundhenke, Christoph
    Schem, Christian
    Bauerschlag, Dirk Olaf
    Weigel, Marion T.
    Wenners, Antonia Sophie
    Schaefer, Fritz Werner
    Tiemann, Katharina
    Hanson, Sven
    Muth, Mathias
    May, Christoph
    Jonat, Walter
    Maass, Nicolai
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [45] Phase II trial of saracatinib in patients (pts) with ER/PR-negative metastatic breast cancer (MBC)
    Traina, T. A.
    Sparano, J. A.
    Caravelli, J.
    Patil, S.
    Abbruzzi, A.
    Hawke, R.
    Bromberg, J.
    Nonemaker, J.
    Norton, L.
    Hudis, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [46] First-line chemotherapy of advanced or metastatic breast cancer (MBC) with docetaxel and doxorubicin in Indonesia: results from A phase II trial
    Abdulmuthalib
    Darwis, Idral
    Prayogo, Nugroho
    Sutjipto
    MEDICAL JOURNAL OF INDONESIA, 2005, 14 (01) : 20 - 25
  • [47] Prospective assessment of cardiac toxicity during a randomized phase II trial of doxorubicin and paclitaxel in metastatic breast cancer
    Hortobagyi, GN
    Willey, J
    Rahman, Z
    Holmes, FA
    Theriault, RL
    Buzdar, AU
    SEMINARS IN ONCOLOGY, 1997, 24 (05) : 65 - 68
  • [48] Phase I/II Gemcitabine (G) with Pegylated Liposomal Doxorubicin (PLD) as first-line therapy in metastatic breast cancer (MBC) in Asian women
    Wong, Zee Wan
    Shah, Valencia A.
    Wong, Nan Soon
    Ang, Peter Cher Siang
    Silverman, Carrie
    Tan, Say Beng
    Cheung, Yin Bun
    Chowbay, Balram
    See, Hui Ti
    Khoo, Kei Siong
    ANNALS OF ONCOLOGY, 2004, 15 : 43 - 43
  • [49] Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer
    Chan, S
    Friedrichs, K
    Noel, D
    Pintér, T
    Van Belle, S
    Vorobiof, D
    Duarte, R
    Gil, MG
    Bodrogi, I
    Murray, E
    Yelle, L
    von Minckwitz, G
    Korec, S
    Simmonds, P
    Buzzi, F
    Mancha, RG
    Richardson, G
    Walpole, E
    Ronzoni, M
    Murawsky, M
    Alakl, M
    Riva, A
    Crown, J
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) : 2341 - 2354
  • [50] Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer
    Tolcher, AW
    Sugarman, S
    Gelmon, KA
    Cohen, R
    Saleh, M
    Isaacs, C
    Young, L
    Healey, D
    Onetto, N
    Slichenmyer, W
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (02) : 478 - 484
12345